Azurity Pharmaceuticals, Inc.

Form 483 issued January 15, 2020 · Wilmington, Massachusetts

Inspection
Jan 8 – Jan 15, 2020
Investigator
Erik W. Koester
Observations
2
Pages
3
FEI number
3003395329

In short: On January 15, 2020, FDA issued a Form 483 with 2 observations to Azurity Pharmaceuticals, Inc. in Wilmington, Massachusetts (FEI 3003395329) after an inspection that ran Jan 8 – Jan 15, 2020. The investigator was Erik W. Koester. Most observations concern laboratory controls and quality system.

At a glance

Laboratory controls and quality system account for 2 of 2 observations.

Laboratory controls1
Quality system1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    The accuracy, sensitivity, specificity and reproducibility of test methods…

  2. 02

    There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Azurity Pharmaceuticals, Inc.?

FDA listed 2 observations on this Form 483, mostly about laboratory controls and quality system. The opening words of each observation are shown on this page.

Who inspected Azurity Pharmaceuticals, Inc.?

Erik W. Koester is named on this Form 483, for the inspection of Jan 8 – Jan 15, 2020. Each investigator has a profile showing what they cite most.

When was Azurity Pharmaceuticals, Inc. inspected by FDA?

The inspection ran Jan 8 – Jan 15, 2020, and the Form 483 is dated January 15, 2020.

How do I get the full Form 483 for Azurity Pharmaceuticals, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free